Different endpoints derived from wearables can require very different wearable sensors.  Unfortunately, qualifying and integrating different wearables often from different vendors can be time-consuming and uncertain.  Learn how Shimmer Research is addressing this challenge by introducing a series of wearables that are all part of its highly flexible Verisense platform.

Founded in 2006, Highthinkmed is the fastest growing clinical CRO in China with over 800 full time employees, providing one-stop clinical services including clinical operation, medical affairs, data management, biostatistics, pharmacovigilance, regulatory affairs etc. Highthinkmed owes its own eCTD system meeting requirements of FDA, EMA and NMPA with a professional team providing eCTD submission services. Highthinkmed welcomes all partners across the world for international collaboration.

This talk will focus on the AI applications in the drug development process, with a focus on designing and executing clinical trials. The discussion will be illustrated by examples and will cover issues, such as data processing and preparation, design of robust AI solutions, and more.

Organizations face numerous challenges in driving AI development at scale across organizations. These include identifying valid use cases, building AI solutions adopted by users and proving ROI from AI initiatives. In this talk, we discuss how applying Decision Intelligence can help resolve some challenges and provide a focused path to building AI, that users trust and adopt. The discussion will include use cases and examples from real projects at IQVIA.

In order to improve productivity throughout the clinical trial execution process, AbbVie is developing a family of Intelligent Process Automation ‘bots’ that execute operational processes in order to free up our teams to work on higher value activities. These bots assist in trial operations tasks such as document quality checks, extraction of statistical data from PDF sources, and more. In this talk I will introduce the audience to five of our family members - Blizzard, Bert, Mater, Ernie, and CeSaR. I will explain how these bots give time back to our teams and walk through how they were developed and deployed.

This presentation will cover some of the numerous exciting applications of AI in drug development, as well as pitfalls to watch out in order to make sure best practices are being followed for robust AI results.

Using AI and analytics, we can speed clinical trial enrollment, accelerate overall clinical development timelines, and reduce costs. An integrated set of advanced analytical tools and processes was developed that allows users to identify trends and make broader inferences about clinical trial feasibility and facilitates more robust and reliable clinical development plans.

Conduct of clinical trials are costly. Significant portion of the cost in a clinical trial is attributed to site monitoring related activities such as source data verification/review during the conduct of the trial. Studies have shown that traditional onsite monitoring at a fixed intervals have resulted in suboptimal efficiencies.  Therefore, exploration of alternate approaches such as evidence-based decision making to optimize the cost and quality have become increasingly important

TransCelerate’s solutions help identify ways intelligent automation technologies can support and improve the execution of pharmacovigilance (PV) activities and processes. Using the Individual Case Safety Reporting (ICSR) process as a case study, we will introduce foundational terminology, attitudes toward intelligent automation, applicable technologies, and validation considerations.

The Janssen Global Development Feasibility team has built a sustainable global model to support every trial with data science and technology at an industrial scale. This presentation will focus on briefly showcasing several tools and algorithms that were built internally to bring unfathomable value and data-driven solutions to trial teams that aids them in making solid decisions on how to operationalize each trial for ultimate success and decreased patient and site burden.